New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents

References

• Dougados M, Baeten D. Spondyloarthrtis. Lancet. 2011;377(9783):2127–2137.
   PubMed Web of Science ®Google Scholar
• Braun J, Sieper J. Classification, diagnosis, and referral of patients with axial spondyloarthritis. Rheum Dis Clin North Am. 2012;38:477–485.
   PubMed Web of Science ®Google Scholar
• Van Der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–368.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Van Der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–783.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Van Der Heijde DM, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25–31.
   PubMed Web of Science ®Google Scholar
• Sieper J. Developments in therapies for sondyloarthritis. Nat Rev Rheumatol. 2012;8:280–287.
   PubMed Web of Science ®Google Scholar
• Zochling J, Van Der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2006;65:442–452.
   PubMed Web of Science ®Google Scholar
• Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359(9313):1187–1193.
   PubMed Web of Science ®Google Scholar
• Davis JC, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum. 2003;48:3230–3236.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo controlled trial. Arthritis Rheum. 2006;54:2136–2146.
   PubMed Web of Science ®Google Scholar
• Inman RD, Davis JC Jr. van der Heijde D et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402–3412.
   PubMed Web of Science ®Google Scholar
• Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNFa agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65:316–320.
   PubMed Web of Science ®Google Scholar
• Sidiropoulos PI, Hatemi G, Song IH, et al. Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3 E initiative in rheumatology involving a broad panel of experts and practicing rheumatologists. Rheumatology. 2008;47:355–361.
   PubMed Web of Science ®Google Scholar
• Braun J, Van Den Berg R, Baraliakos X, et al. EULAR 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896–904.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Van Den Berg R, Braun J, et al. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology. 2012;51:1378–1387.
   PubMed Web of Science ®Google Scholar
• Heldmann F, Dybowski F, Sarachasi-Zender E, et al. Update on biological therapy in the management of axial spondyloarthritis. Curr Rheumatol Rep. 2010;12:325–331.
   PubMedGoogle Scholar
• Sieper J, Van Der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomized placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72:815–822.
   PubMed Web of Science ®Google Scholar
• Landewe R, Barun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double blind randomised placebo controlled phase 3 study. Ann Rheum Dis. 2014;73:39–47.
   PubMed Web of Science ®Google Scholar
• Dougados M, Van Der Heijde D, Sieper J, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiogarphic axial spondyloarthritis. A multicentre, randomised, double blind, placebo controlled trial. Arthritis Rheumatol. 2014;66:2091–2102.
   PubMed Web of Science ®Google Scholar
• Sieper J, Van Der Heijde D, Dougados M, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2015;67:2702–2712.
   PubMed Web of Science ®Google Scholar
• Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–1612.
   PubMed Web of Science ®Google Scholar
• Emery P, Vencovský J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73:817–823.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti TNF agents infliximab and etanercept. Arthritis Rheum. 2005;52:2447–2451.
   PubMed Web of Science ®Google Scholar
• Sieper J. Can structural damage be prevented in ankylosing spondylitis. Curr Opin Rheumatol. 2009;21:335–339.
   PubMed Web of Science ®Google Scholar
• Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65:2645–2654.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004;63:665–670.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Schwarzlose S, Hilgert ES, et al. MRI in predicting a major clinical response to anti tumor necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis. 2008;67:1276–1281.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73:6–16.
   PubMed Web of Science ®Google Scholar
• Van Den Bosch F, Deodhar A. Treatment of spondyloarthritis beyond TNF-alpha blockade. Best Pract Res Clin Rheumatol. 2014;28:819–827.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Jhangri GS, Fitzgerald AA, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum. 2002;46:766–773.
   PubMed Web of Science ®Google Scholar
• Toussirot É. Biologics in spondyloarthritis: tNFα inhibitors and other agents. Immunotherapy. 2015;7:669–681.
   PubMed Web of Science ®Google Scholar
• Braun J, Kiltz U, Heldmann F, et al. Emerging drugs for the treatment of axial and peripheral spondyloarthritis. Expert Opin Emerg Drugs. 2015;20:1–14.
   PubMed Web of Science ®Google Scholar
• Yeremenko N, Paramarta JE, Baeten D. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis. Curr Opin Rheumatol. 2014;26:361–370.
   PubMed Web of Science ®Google Scholar
• Paine A, Ritchlin CT. Targeting the interleukin-23/17 axis in axial spondyloarthritis. Curr Opin Rheumatol. 2016;28:359–367.
   PubMed Web of Science ®Google Scholar
• Burton PR, Clayton DG, Cardon LR, et al.; Wellcome Trust Case Control Consortium.; Australo-Anglo-American Spondylitis Consortium (TASC). Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007;39:1329–1337.
   PubMed Web of Science ®Google Scholar
• DeLay ML, Turner MJ, Klenk EI, et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 2009;60:2633–2643.
   PubMed Web of Science ®Google Scholar
• Bowness P, Ridley A, Shaw J, et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol. 2011;186:2672–2680.
   PubMed Web of Science ®Google Scholar
• Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. PLoS One. 2012;7:e31000.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li YG, Li YH, et al. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009;60:1647–1656.
   PubMed Web of Science ®Google Scholar
• Appel H, Maier R, Bleil J, et al. In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. Arthritis Rheum. 2013;65:1522–1529.
   PubMed Web of Science ®Google Scholar
• Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 2012;64:99–109.
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18:1069–1076.
   PubMed Web of Science ®Google Scholar
• Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond). 2012;122:487–511.
   PubMed Web of Science ®Google Scholar
• Venken K, Elewaut D. New immune cells in spondyloarthritis: key players or innocent bystanders? Best Pract Res Clin Rheumatol. 2015;29:706–714.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Kiltz U. Secukinumab (AIN457) in the treatment of ankylosing spondylitis. Expert Opin Biol Ther. 2016;16:711–722.
   PubMed Web of Science ®Google Scholar
• Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705–1713.
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534–2548.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Borah B, Braun J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis. 2016;75:408–412.
   PubMed Web of Science ®Google Scholar
• Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis. 2016Aug;31. Epub ahead of print
   Google Scholar
• Weber J, Keam SJ. Ustekinumab. BioDrugs. 2009;23:53–61.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73:817–823.
   PubMed Web of Science ®Google Scholar
• A study to evaluate the efficacy and safety of ustekinumab in the treatment of anti TNFalpha naive participants with active radiographic axial spondyloarthritis. Clinical trials.gov NCT02437162.
   Google Scholar
• A study to evaluate the efficacy and safety of ustekinumab in the treatment of  anti-TNFalpha refractory participants with active radiographic axial spondyloarthritis. Clinical trials.gov NCT02438787.
   Google Scholar
• An efficacy and safety study of ustekinumab in participants with active non radiographic axial spondyloarthritis. Clinical trials.gov NCT02407223.
   Google Scholar
• Kavanaugh A, Puig L, Gottlieb AB, et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann Rheum Dis. 2016;75:1984–1988.
   PubMed Web of Science ®Google Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583–1590.
   PubMed Web of Science ®Google Scholar
• Mease PJ. Apremilast: a phosphodiesterase 4 inhibitor for the treatment of psoriatic arthritis. Rheumatol Ther. 2014;1:1–20.
   PubMedGoogle Scholar
• Pathan E, Abraham S, Van Rossen E, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis. 2013;72:1475–1480.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase 2, 16 week, randomized, placebo controlled, dose ranging study. Arthritis Rheum. 2015;67(Suppl):5L.
   Google Scholar
• Paramarta JE, Turina MC, Noordenbos T, et al. A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis. J Transl Med. 2016;14:308.
   PubMed Web of Science ®Google Scholar
• Sieper J, Poddubnyy D. New evidence on the management of spondyloarthritis. Nat Rev Rheumatol. 2016;12:282–295.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Reveille JD, Van Den Bosch F, et al. The concept of axial spondyloarthritis. Joint statement of the spondyloarthritis research and treatment network and the assessment of spondyloarthritis international society in response to the US Food and Drug Administration’s comments and concerns. Arthritis Rheumatol. 2014;66:2649–2656.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Deodhar A, Braun J, et al. Effect of interleukin-17A inhibition on spinal radiographic changes through 2 years in patients with active ankylosing spondylitis: results of a phase 3 study with secukinumab. Arthritis Rheum. 2015;67(Suppl):6L.
   Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody for moderate to severe Crohn’s disease: unexpected results of a randomised double blind, placebo controlled trial. Gut. 2012;61:1693–1700.
   PubMed Web of Science ®Google Scholar
• Braun J. New targets in psoriatic arthritis. Rheumatology. 2016;55:ii30–ii37.
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, Siebert S, McInnes IB. Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases. Annu Rev Med. 2016;67:337–353.
   PubMed Web of Science ®Google Scholar
• Study of ixekizumab in participants with active ankylosing spondylitis. ClinicalTrials.gov NCT01870284.
   Google Scholar
• Torres T, Romanelli M, Chiricozzi A. A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin Investig Drugs. 2016;25(7):751–754.
   PubMed Web of Science ®Google Scholar
• Bauer E, Lucier J, Furts DE. Brodalumab, an anti-IL17RA monoclonal antibody for psoriasis and psoriatic arthritis. Expert Opin Biol Ther. 2015;15:883–893.
   PubMed Web of Science ®Google Scholar